AAAAAA
Results: 26-45/45
Authors:
Rowinsky, EK
Citation: Ek. Rowinsky, The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents, DRUGS, 60, 2000, pp. 1-14
Authors:
John, W
Picus, J
Blanke, CD
Clark, JW
Schulman, LN
Rowinsky, EK
Thornton, DE
Loehrer, PJ
Citation: W. John et al., Activity of multitargeted antifolate (Pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma - Results from a phase II study, CANCER, 88(8), 2000, pp. 1807-1813
Authors:
Fracasso, PM
Tan, BR
Grieff, M
Stephenson, J
Liapis, H
Umbeck, NL
Von Hoff, DD
Rowinsky, EK
Citation: Pm. Fracasso et al., Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma, J NAT CANC, 91(20), 1999, pp. 1779-1780
Authors:
Britten, CD
Rowinsky, EK
Baker, SD
Agarwala, SS
Eckardt, JR
Barrington, R
Diab, SG
Hammond, LA
Johnson, T
Villalona-Calero, M
Fraass, U
Statkevich, P
Von Hoff, DD
Eckhardt, SG
Citation: Cd. Britten et al., A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies, CLIN CANC R, 5(7), 1999, pp. 1629-1637
Authors:
Rowinsky, EK
Jiroutek, M
Bonomi, P
Johnson, D
Baker, SD
Citation: Ek. Rowinsky et al., Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin, CLIN CANC R, 5(4), 1999, pp. 767-774
Authors:
Rowinsky, EK
Citation: Ek. Rowinsky, On pushing the outer edge of the outer edge of Paclitaxel's dosing envelope, CLIN CANC R, 5(3), 1999, pp. 481-486
Authors:
Diab, SG
Baker, SD
Joshi, A
Burris, HA
Cobb, PW
Villalona-Calero, RA
Eckhardt, SG
Weiss, GR
Rodriguez, GI
Drengler, R
Kraynak, M
Hammond, L
Finizio, M
Von Hoff, DD
Rowinsky, EK
Citation: Sg. Diab et al., A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors, CLIN CANC R, 5(2), 1999, pp. 299-308
Authors:
Baker, SD
Wirth, M
Statkevich, P
Reidenberg, P
Alton, K
Sartorius, SE
Dugan, M
Cutler, D
Batra, V
Grochow, LB
Donehower, RC
Rowinsky, EK
Citation: Sd. Baker et al., Absorption, metabolism, and excretion of C-14-temozolomide following oral administration to patients with advanced cancer, CLIN CANC R, 5(2), 1999, pp. 309-317
Authors:
Villalona-Calero, MA
Petit, T
Kuhn, J
Cobb, P
Kraynak, M
Eckhardt, SG
Drengler, R
Simmons, C
Santabarbara, P
Von Hoff, DD
Rowinsky, EK
Citation: Ma. Villalona-calero et al., A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies, CLIN CANC R, 5(11), 1999, pp. 3369-3378
Authors:
Hidalgo, M
Izbicka, E
Eckhardt, SG
MacDonald, JR
Cerna, C
Gomez, L
Rowinsky, EK
Weitman, SD
Von Hoff, DD
Citation: M. Hidalgo et al., Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units, ANTI-CANC D, 10(9), 1999, pp. 837-844
Authors:
Lawrence, RA
Izbicka, E
De Jager, RL
Tohgo, A
Clark, GM
Weitman, SD
Rowinsky, EK
Von Hoff, DD
Citation: Ra. Lawrence et al., Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells, ANTI-CANC D, 10(7), 1999, pp. 655-661
Authors:
Hidalgo, M
Izbicka, E
Cerna, C
Gomez, L
Rowinsky, EK
Weitman, SD
Von Hoff, DD
Citation: M. Hidalgo et al., Comparative activity of the cyclopropylpyrroloindole compounds adozelesin,bizelesin and carzelesin in a human tumor colony-forming assay, ANTI-CANC D, 10(3), 1999, pp. 295-302
Authors:
Petit, T
Aylesworth, C
Burris, H
Ravdin, P
Rodriguez, G
Smith, L
Peacock, N
Smetzer, L
Bellet, R
Von Hoff, DD
Rowinsky, EK
Citation: T. Petit et al., A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies, ANN ONCOL, 10(2), 1999, pp. 223-229
Authors:
Rowinsky, EK
Citation: Ek. Rowinsky, Novel radiation sensitizers targeting tissue hypoxia, ONCOLOGY-NY, 13(10), 1999, pp. 61-70
Authors:
Hammond, LA
Eckardt, JR
Baker, SD
Eckhardt, SG
Dugan, M
Forral, K
Reidenberg, P
Statkevich, P
Weiss, GR
Rinaldi, DA
Von Hoff, DD
Rowinsky, EK
Citation: La. Hammond et al., Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies, J CL ONCOL, 17(8), 1999, pp. 2604-2613
Authors:
Villalona-Calero, MA
Weiss, GR
Burris, HA
Kraynak, M
Rodrigues, G
Drengler, RL
Eckhardt, SG
Reigner, B
Moczygemba, J
Burger, HU
Griffin, T
Von Hoff, DD
Rowinsky, EK
Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies, J CL ONCOL, 17(6), 1999, pp. 1915-1925
Authors:
Eckhardt, SG
Rizzo, J
Sweeney, KR
Cropp, G
Baker, SD
Kraynak, MA
Kuhn, JG
Villalona-Calero, MA
Hammond, L
Weiss, G
Thurman, A
Smith, L
Drengler, R
Eckardt, JR
Moczygemba, J
Hannah, AL
Von Hoff, DD
Rowinsky, EK
Citation: Sg. Eckhardt et al., Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors, J CL ONCOL, 17(4), 1999, pp. 1095-1104
Authors:
Rowinsky, EK
Windle, JJ
Von Hoff, DD
Citation: Ek. Rowinsky et al., Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development, J CL ONCOL, 17(11), 1999, pp. 3631-3652
Authors:
Britten, CD
Izbicka, E
Hilsenbeck, S
Lawrence, R
Davidson, K
Cerna, C
Gomez, L
Rowinsky, EK
Weitman, S
Von Hoff, DD
Citation: Cd. Britten et al., Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay, CANC CHEMOT, 44(2), 1999, pp. 105-110
Authors:
Britten, CD
Hilsenbeck, SG
Eckhardt, SG
Marty, J
Mangold, G
MacDonald, JR
Rowinsky, EK
Von Hoff, DD
Weitman, S
Citation: Cd. Britten et al., Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model, CANCER RES, 59(5), 1999, pp. 1049-1053